source
- Novartis licenses Abogen’s mRNA CD19×CD3 engager in $575M upfront dealAbogen Biosciences saw its COVID vaccine miss the market, prompting questions about whether its mRNA platform could be leveraged for other therapies. Novartis agreed to pay $575 million up front f…
- Hengrui secures $15.2 billion Bristol Myers deal and pivots to co-development with Western partnersHengrui Pharmaceuticals has become a leading source of innovative drugs in China, outpacing many peers in the current licensing boom. In May the company signed a $15.2 billion licensing pact with…